Level 1 Dosage News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Level 1 Dosage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Level 1 Dosage Today - Breaking & Trending Today

Phase 1/2 Findings Highlight RGX-202's Safety, Impact on Key Duchenne Biomarkers

Published: October 21, 2023

RGX-202, a gene therapy for Duchenne muscular dystrophy, was well tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage.

Source: ajmc.com

Related Topics:

United StatesAravindhan VeerapandiyanOlivier DanosManufacturing Innovation CenterWorld Muscle SocietyInternational CongressArkansas ChildrenNorth Star Ambulatory AssessmentInnovation CenterRgx 202Duchenne Muscular DystrophyLevel 1 DosageSerum Creatine KinaseAffinity Duchenne